NIAGEN BIOSCIENCE INC (NAGE) Stock Fundamental Analysis
NASDAQ:NAGE - US1710774076 - Common Stock
9.6 USD
+0.22 (+2.35%)
9.5 USD
-0.1 (-1.04%)
We assign a fundamental rating of 6 out of 10 to NAGE. NAGE was compared to 55 industry peers in the Life Sciences Tools & Services industry. While NAGE has a great health rating, its profitability is only average at the moment. NAGE is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes NAGE very considerable for growth investing!
1. Profitability
1.1 Basic Checks
NAGE had positive earnings in the past year.
In the past year NAGE had a positive cash flow from operations.
NAGE had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NAGE reported negative operating cash flow in multiple years.
1.2 Ratios
NAGE's Return On Assets of 19.37% is amongst the best of the industry. NAGE outperforms 94.55% of its industry peers.
NAGE's Return On Equity of 27.62% is amongst the best of the industry. NAGE outperforms 92.73% of its industry peers.
NAGE's Return On Invested Capital of 19.03% is amongst the best of the industry. NAGE outperforms 92.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.37% | ||
| ROE | 27.62% | ||
| ROIC | 19.03% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NAGE has a Profit Margin of 15.24%. This is amongst the best in the industry. NAGE outperforms 85.45% of its industry peers.
NAGE has a Operating Margin of 14.33%. This is in the better half of the industry: NAGE outperforms 74.55% of its industry peers.
NAGE's Gross Margin of 63.62% is amongst the best of the industry. NAGE outperforms 83.64% of its industry peers.
In the last couple of years the Gross Margin of NAGE has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.33% | ||
| PM (TTM) | 15.24% | ||
| GM | 63.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
NAGE has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
NAGE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NAGE has more shares outstanding
The debt/assets ratio for NAGE has been reduced compared to a year ago.
2.2 Solvency
NAGE has an Altman-Z score of 16.49. This indicates that NAGE is financially healthy and has little risk of bankruptcy at the moment.
NAGE has a Altman-Z score of 16.49. This is amongst the best in the industry. NAGE outperforms 98.18% of its industry peers.
There is no outstanding debt for NAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.49 |
ROIC/WACC1.85
WACC10.31%
2.3 Liquidity
NAGE has a Current Ratio of 3.88. This indicates that NAGE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NAGE (3.88) is better than 63.64% of its industry peers.
A Quick Ratio of 3.24 indicates that NAGE has no problem at all paying its short term obligations.
NAGE has a Quick ratio of 3.24. This is in the better half of the industry: NAGE outperforms 61.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.88 | ||
| Quick Ratio | 3.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1150.00% over the past year.
NAGE shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.89%.
The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)1150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21050%
Revenue 1Y (TTM)35.89%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%36.84%
3.2 Future
Based on estimates for the next years, NAGE will show a very strong growth in Earnings Per Share. The EPS will grow by 56.39% on average per year.
NAGE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.00% yearly.
EPS Next Y36.68%
EPS Next 2Y66.72%
EPS Next 3Y56.39%
EPS Next 5YN/A
Revenue Next Year29.04%
Revenue Next 2Y25.29%
Revenue Next 3Y23%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 45.71, which means the current valuation is very expensive for NAGE.
NAGE's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of NAGE to the average of the S&P500 Index (27.03), we can say NAGE is valued expensively.
With a Price/Forward Earnings ratio of 34.54, NAGE can be considered very expensive at the moment.
NAGE's Price/Forward Earnings is on the same level as the industry average.
NAGE is valuated expensively when we compare the Price/Forward Earnings ratio to 22.54, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.71 | ||
| Fwd PE | 34.54 |
4.2 Price Multiples
NAGE's Enterprise Value to EBITDA ratio is in line with the industry average.
63.64% of the companies in the same industry are more expensive than NAGE, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.57 | ||
| EV/EBITDA | 39.41 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of NAGE may justify a higher PE ratio.
NAGE's earnings are expected to grow with 56.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.25
PEG (5Y)N/A
EPS Next 2Y66.72%
EPS Next 3Y56.39%
5. Dividend
5.1 Amount
NAGE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.6
+0.22 (+2.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners33.23%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change6.42%
Market Cap765.60M
Analysts85.45
Price Target16.36 (70.42%)
Short Float %7.77%
Short Ratio3.61
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)216.49%
Min EPS beat(2)180.11%
Max EPS beat(2)252.87%
EPS beat(4)4
Avg EPS beat(4)315.75%
Min EPS beat(4)180.11%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)196.75%
EPS beat(12)12
Avg EPS beat(12)140.83%
EPS beat(16)13
Avg EPS beat(16)103.25%
Revenue beat(2)2
Avg Revenue beat(2)8.99%
Min Revenue beat(2)7.71%
Max Revenue beat(2)10.27%
Revenue beat(4)4
Avg Revenue beat(4)7.72%
Min Revenue beat(4)6.07%
Max Revenue beat(4)10.27%
Revenue beat(8)4
Avg Revenue beat(8)1.25%
Revenue beat(12)6
Avg Revenue beat(12)1.27%
Revenue beat(16)6
Avg Revenue beat(16)-0.38%
PT rev (1m)6.08%
PT rev (3m)77.73%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)-52%
EPS NY rev (1m)3.08%
EPS NY rev (3m)8.65%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)1.66%
Revenue NY rev (1m)1.6%
Revenue NY rev (3m)2.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.71 | ||
| Fwd PE | 34.54 | ||
| P/S | 6.58 | ||
| P/FCF | 36.57 | ||
| P/OCF | 36.09 | ||
| P/B | 11.93 | ||
| P/tB | 11.98 | ||
| EV/EBITDA | 39.41 |
EPS(TTM)0.21
EY2.19%
EPS(NY)0.28
Fwd EY2.9%
FCF(TTM)0.26
FCFY2.73%
OCF(TTM)0.27
OCFY2.77%
SpS1.46
BVpS0.8
TBVpS0.8
PEG (NY)1.25
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.37% | ||
| ROE | 27.62% | ||
| ROCE | 24.09% | ||
| ROIC | 19.03% | ||
| ROICexc | 148.37% | ||
| ROICexgc | 153.27% | ||
| OM | 14.33% | ||
| PM (TTM) | 15.24% | ||
| GM | 63.62% | ||
| FCFM | 18% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 35.42% | ||
| Cap/Sales | 0.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 121.54% | ||
| Profit Quality | 118.08% | ||
| Current Ratio | 3.88 | ||
| Quick Ratio | 3.24 | ||
| Altman-Z | 16.49 |
F-Score7
WACC10.31%
ROIC/WACC1.85
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21050%
EPS Next Y36.68%
EPS Next 2Y66.72%
EPS Next 3Y56.39%
EPS Next 5YN/A
Revenue 1Y (TTM)35.89%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%36.84%
Revenue Next Year29.04%
Revenue Next 2Y25.29%
Revenue Next 3Y23%
Revenue Next 5YN/A
EBIT growth 1Y823.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year585.77%
EBIT Next 3Y156.77%
EBIT Next 5YN/A
FCF growth 1Y1146.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y960.55%
OCF growth 3YN/A
OCF growth 5YN/A